Prescription drug · ANDA
Acetazolamide NDC 10135-831
Acetazolamide 250 mg/1 · Tablet · Oral · Marlex Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 10135-831-01 | 10135083101 | 100 TABLET in 1 BOTTLE (10135-831-01)Marketed from Feb 1, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Acetazolamide
- Generic name (nonproprietary)
- acetazolamide
- Active ingredients
- Acetazolamide — 250 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Marlex Pharmaceuticals, Inc.NDC labeler code 10135
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 217197
- Marketing start
- Listing expires
- Other FDA classes
- Carbonic Anhydrase Inhibitors (Mechanism)Sulfonamides (Chemical structure)
- Identifiers
- Product ID 10135-831_4a03f386-e570-d4cb-e063-6394a90a8228SPL ID 4a03f386-e570-d4cb-e063-6394a90a8228SPL set ID 4a03f35d-bfcb-77ff-e063-6294a90a4f06RxCUI 197303, 197304UNII O3FX965V0I
- Pharmacologic class
- Carbonic Anhydrase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N410135083101followed by a unit qualifier and the quantityPackage 10135-0831-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent.
Excerpt only. Read the full label for complete information.
About NDC 10135-831
- What is NDC 10135-831?
- 10135-831 is the product NDC for Acetazolamide, Acetazolamide 250 mg/1 tablet, listed with the FDA by Marlex Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Acetazolamide.
- What is the active ingredient?
- Acetazolamide.
- Who is the labeler?
- Marlex Pharmaceuticals, Inc., NDC labeler code 10135. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Acetazolamide?
- 71 other product NDCs are listed under this name. See all Acetazolamide NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Acetazolamide products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Acetazolamideacetazolamide sodium | Acetazolamide sodium 500 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | Mylan Institutional LLC | 72078-092 | 72078-0092-50 |
| Acetazolamide | Acetazolamide 500 mg/1 | Capsule, Extended releaseOral | REMEDYREPACK INC. | 70518-4646 | 70518-4646-00 |
| Acetazolamide | Acetazolamide 125 mg/1 | TabletOral | Marlex Pharmaceuticals, Inc. | 10135-830 | 10135-0830-01 |
| Acetazolamideacetazolamide sodium | Acetazolamide sodium 500 mg/5mL | Injection, Powder, For solutionIntravenous | Sagent Pharmaceuticals | 25021-839 | 25021-0839-20 |
| Acetazolamide | Acetazolamide sodium 500 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | Gland Pharma Limited | 68083-661 | 68083-0661-01 |
| Acetazolamide | Acetazolamide 125 mg/1 | TabletOral | Aurobindo Pharma Limited | 59651-905 | 59651-0905-01 |
| Acetazolamide | Acetazolamide 250 mg/1 | TabletOral | Aurobindo Pharma Limited | 59651-906 | 59651-0906-01 |
| Acetazolamide | Acetazolamide 125 mg/1 | TabletOral | Aarkish Pharmaceuticals NJ Inc. | 81005-104 | 81005-0104-0181005-0104-10 |
| Acetazolamide | Acetazolamide 250 mg/1 | TabletOral | Aarkish Pharmaceuticals NJ Inc. | 81005-105 | 81005-0105-0181005-0105-10 |
| Acetazolamide | Acetazolamide 125 mg/1 | TabletOral | Ajanta Pharma USA Inc. | 27241-132 | 27241-0132-04 |
Other NDCs under ANDA 217197
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Acetazolamide | Acetazolamide 125 mg/1 | TabletOral | Marlex Pharmaceuticals, Inc. | 10135-830 |
| Acetazolamide | Acetazolamide 125 mg/1 | TabletOral | Aarkish Pharmaceuticals NJ Inc. | 81005-104 |
| Acetazolamide | Acetazolamide 250 mg/1 | TabletOral | Aarkish Pharmaceuticals NJ Inc. | 81005-105 |